Ethinyl Estradiol and Norelgestromin

Brand names: Norelgestromin And Ethinyl Estradiol ยท Active ingredient: Norelgestromin, Ethinyl Estradiol

In short: Norelgestromin and ethinyl estradiol transdermal system is indicated for the prevention of pregnancy in women with a body mass index (BMI) < 30 kg/m2 for whom a combined hormonal contraceptive is appropriate. Limitations of Use: Norelgestromin and ethinyl estradiol transdermal system may be less eff

Forms & strengthsNorelgestromin and ethinyl estradiol transdermal system is available in one strength of 150 mcg/day norelgestromin (NGMN) and 35 mcg/day ethinyl estradiol (EE). โ€ฆ
LabelZydus Pharmaceuticals USA Inc.
Label updatedApr 17, 2026

What is Ethinyl Estradiol and Norelgestromin used for?

Norelgestromin and ethinyl estradiol transdermal system is indicated for the prevention of pregnancy in women with a body mass index (BMI) < 30 kg/m2 for whom a combined hormonal contraceptive is appropriate.

Limitations of Use:

Norelgestromin and ethinyl estradiol transdermal system may be less effective in preventing pregnancy in women who weigh 198 lbs (90 kg) or more. Norelgestromin and ethinyl estradiol transdermal system is contraindicated for use in women with BMI โ‰ฅ 30 kg/m2 .

โš  Boxed warning (FDA's strongest warning)

โ€ข

Cigarette Smoking and Serious Cardiovascular Events

Cigarette smoking increases the risk of serious cardiovascular events from hormonal contraceptive use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including norelgestromin and ethinyl estradiol transdermal system, are contraindicated in women who are over 35 years of age and smoke .

โ€ข

Contraindicated in Women with a BMI โ‰ฅ 30 kg/m2

Norelgestromin and ethinyl estradiol transdermal system is contraindicated in women with a BMI โ‰ฅ 30 kg/m2. The risk of VTE may be greater with

norelgestromin and ethinyl estradiol transdermal in women with a BMI โ‰ฅ 30 kg/m2 compared to women with a lower BMI .

Ethinyl Estradiol and Norelgestromin dosage

To achieve maximum contraceptive effectiveness, norelgestromin and ethinyl estradiol transdermal system must be used exactly as directed.

Complete instructions to facilitate patient counseling on proper system usage may be found in the FDA-Approved Patient Labeling.

The norelgestromin and ethinyl estradiol transdermal system uses a 28-day (4-week) cycle. A new patch is applied each week for 3 weeks (21 total days). Week 4 is patch-free. Withdrawal bleeding is expected during this time.

Every new patch should be applied on the same day of the week. This day is known as the "Patch Change Day." For example, if the first patch is applied on a Monday, all subsequent patches should be applied on a Monday. Only one patch should be worn at a time.

Do not cut, damage or alter the norelgestromin and ethinyl estradiol transdermal system patch in any way. If the norelgestromin and ethinyl estradiol transdermal system patch is cut, damaged or altered in size, contraceptive efficacy may be impaired.

On the day after Week 4 ends, a new 4-week cycle is started by applying a new patch. Under no circumstances should there be more than a 7-day patch-free interval between dosing cycles.

There are multiple options for starting the Norelgestromin and Ethinyl Estradiol transdermal system, and the woman should choose the option that is most appropriate :

Table 1: Instructions for Administration

Starting Norelgestromin and Ethinyl Estradiol Transdermal System in women with no current use of hormonal contraception

The woman has two options for starting the patch and she should choose the option that is right for her:

First Day Start

The woman should apply her first patch during the first 24 hours of her menstrual period. If a patch is applied after the first 24 hours of menstruation, non-hormonal back-up contraception (such as condoms and spermicide, or diaphragm and spermicide) is needed for the first 7 days of the first cycle only.

The woman should apply a new patch each week for three weeks (21 total days). Every new patch should be applied on the same day of the week. This day is known as the "Patch Change Day." For example, if the first patch is applied on a Monday, all subsequent patches should be applied on a Monday. Only one patch should be worn at a time.

No patch is worn during Week Four (the "Patch-Free Week"). Withdrawal bleeding is expected during this time.

On the day after Week 4 ends, a new 4-week cycle is started by applying a new patch. Under no circumstances should there be more than a 7-day patch-free interval between dosing cycles.

Sunday Start

The woman should apply her first patch on the first Sunday after her menstrual period begins. โ€ฆ

How to take Ethinyl Estradiol and Norelgestromin โ€” instructions & advice from the label

See FDA-approved patient labeling (Patient Information and Instructions for Use)

Counsel patients about the following information:

Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive use, and that women who are over 35 years old and smoke should not use combined hormonal contraceptives.

The use of CHCs increases the risk of VTE. However, pregnancy increases the risk of VTE as much or more than the use of CHCs. The risk of VTE in women using CHCs is 3 to 12 cases per 10,000 woman-years. The risk of VTE is highest during the first year of use of CHCs and when restarting hormonal contraception after a break of 4 weeks or longer. The risk of thromboembolic disease due to CHCs gradually disappears after use is discontinued.

Norelgestromin and ethinyl estradiol transdermal system does not protect against HIV infection (AIDS) and other sexually transmitted infections.

The Warnings and Precautions associated with combined hormonal contraceptives. โ€ฆ

Warnings & precautions

Do not take this medicine if: Norelgestromin and ethinyl estradiol transdermal system is contraindicated in females who are known to have or develop the following conditions:

โ— At high risk of arterial or venous thromboembolic events. Examples include women who:

โ—‹ Smoke, if over age 35

โ—‹ Have deep vein thrombosis or pulmonary embolism, now or in the past

โ—‹ Have inherited or acquired hypercoagulopathies

โ—‹ Have cerebrovascular disease

โ—‹ Have coronary artery disease

โ—‹ Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation)

โ—‹ Have uncontrolled hypertension

โ—‹ Have diabetes mellitus with vascular disease

โ—‹ Have headaches with focal neurological symptoms or have migraine headaches with aura

โ–  Women over age 35 with any migraine headaches

โ— Body Mass Index โ‰ฅ 30 kg/m2

โ— Liver tumors, benign or malignant, or liver disease [see Warnings and Precautions (5.3), Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)]

โ— Undiagnosed abnormal uterine bleeding

โ— Pregnancy, because there is no reason to use hormonal contraceptives during pregnancy

โ— Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive

โ— Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for alanine aminotransferase (ALT) elevations

Stop norelgestromin and ethinyl estradiol transdermal system if an arterial or venous thromboembolic event (VTE) occurs.

Stop norelgestromin and ethinyl estradiol transdermal system if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately. โ€ฆ

Ethinyl Estradiol and Norelgestromin side effects

The following serious adverse reactions with the use of combination hormonal contraceptives, including norelgestromin and ethinyl estradiol transdermal system, are discussed elsewhere in the labeling:

Serious cardiovascular events and stroke

Vascular events, including venous and arterial thromboembolic events

Liver disease

Adverse reactions commonly reported by users of combination hormonal contraceptives are:

Irregular uterine bleeding

Nausea

Breast tenderness

Headache

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The data described below reflect exposure to norelgestromin and ethinyl estradiol transdermal system in 3330 sexually active women (3322 of whom had safety data) who participated in three Phase 3 clinical trials designed to evaluate contraceptive efficacy and safety. These subjects received six or 13 cycles of contraception (norelgestromin and ethinyl estradiol transdermal system or an oral contraceptive comparator in 2 of the trials). The women ranged in age from 18 to 45 years and were predominantly white (91%). โ€ฆ

Drug interactions

Consult the labeling of concurrently-used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations.

Substances Decreasing the Plasma Concentrations of CHCs and Potentially Diminishing the Efficacy of CHCs

Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the plasma concentrations of CHCs and potentially diminish the effectiveness of CHCs or increase breakthrough bleeding. Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. Interactions between hormonal contraceptives and other drugs may lead to breakthrough bleeding and/or contraceptive failure. Counsel women to use an alternative method of contraception or a back-up method when enzyme inducers are used with CHCs, and to continue back-up contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability. โ€ฆ

About this medicine

Norelgestromin and ethinyl estradiol transdermal system is a transdermal system with a contact surface area of 15.75 cm2. It contains 4.678 mg norelgestromin, USP (NGMN) and 0.53 mg ethinyl estradiol, USP (EE), and its delivery rate is approximately 150 mcg of NGMN and 35 mcg of EE per day. Systemic exposures (as measured by area under the curve [AUC] and steady state concentration [Css]) of NGMN and EE during use of norelgestromin and ethinyl estradiol transdermal system are higher and the Cmax is lower than those produced by an oral contraceptive containing NGM 250 mcg / EE 35 mcg.

Norelgestromin and ethinyl estradiol transdermal system is a thin, matrix-type transdermal system consisting of three layers. The backing layer is composed of a peach flexible film consisting of a pigmented polyethylene outer layer and a polyester inner layer. It provides structural support and protects the middle adhesive layer from the environment. The middle layer contains crospovidone, lauryl lactate, polyisobutylene/polybutene adhesive and non-woven polyester fabric as inactive components. โ€ฆ

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label โ€” it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 10fa1458-c8ed-4197-922a-1ba7271d2b02. Read the full official label on DailyMed.

Related medicines

Levothyroxine Ergocalciferol Estradiol Ethinyl Estradiol and Norethindrone Alendronate Testosterone Thyroid Norethindrone